VEGFA and cancer: Together with the early obtained results that Rego decreased VEGF in some CRC cell lines with no effect on the CD133 levels in all tested cell lines (Fig. 3f), our findings indicated that any of VEGF and CD133 might be able to support functional residual cancer cells, leading to CRCs recurrence, and that CADPE broadly downregulates oncoproteins including ones supporting residual disease through the inhibition of the three key TFs and the Cap-dependent translation.